Rani Therapeutics (RANI) Competitors $2.05 -0.01 (-0.49%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RANI vs. PASG, CHMA, PYXS, KRRO, TSHA, FHTX, TNGX, VERV, LRMR, and CGCShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Passage Bio (PASG), Chiasma (CHMA), Pyxis Oncology (PYXS), Korro Bio (KRRO), Taysha Gene Therapies (TSHA), Foghorn Therapeutics (FHTX), Tango Therapeutics (TNGX), Verve Therapeutics (VERV), Larimar Therapeutics (LRMR), and Canopy Growth (CGC). These companies are all part of the "medical" sector. Rani Therapeutics vs. Passage Bio Chiasma Pyxis Oncology Korro Bio Taysha Gene Therapies Foghorn Therapeutics Tango Therapeutics Verve Therapeutics Larimar Therapeutics Canopy Growth Passage Bio (NASDAQ:PASG) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Which has higher earnings and valuation, PASG or RANI? Rani Therapeutics has higher revenue and earnings than Passage Bio. Rani Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPassage BioN/AN/A-$102.06M-$1.17-0.44Rani Therapeutics$2.72M40.25-$33.97M-$1.06-1.93 Is PASG or RANI more profitable? Passage Bio's return on equity of -72.53% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Passage BioN/A -72.53% -52.10% Rani Therapeutics N/A -219.64%-56.71% Does the MarketBeat Community favor PASG or RANI? Passage Bio received 20 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 81.58% of users gave Rani Therapeutics an outperform vote while only 68.00% of users gave Passage Bio an outperform vote. CompanyUnderperformOutperformPassage BioOutperform Votes5168.00% Underperform Votes2432.00% Rani TherapeuticsOutperform Votes3181.58% Underperform Votes718.42% Which has more volatility and risk, PASG or RANI? Passage Bio has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Does the media prefer PASG or RANI? In the previous week, Rani Therapeutics had 1 more articles in the media than Passage Bio. MarketBeat recorded 6 mentions for Rani Therapeutics and 5 mentions for Passage Bio. Rani Therapeutics' average media sentiment score of 0.27 beat Passage Bio's score of -0.60 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Rani Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in PASG or RANI? 53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 53.3% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate PASG or RANI? Passage Bio presently has a consensus price target of $9.00, suggesting a potential upside of 1,652.00%. Rani Therapeutics has a consensus price target of $11.71, suggesting a potential upside of 471.43%. Given Passage Bio's higher possible upside, analysts clearly believe Passage Bio is more favorable than Rani Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryRani Therapeutics beats Passage Bio on 10 of the 17 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.48M$6.43B$5.05B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio-1.9310.41123.8917.66Price / Sales40.25243.791,181.4274.22Price / CashN/A22.1633.6632.53Price / Book4.025.474.684.68Net Income-$33.97M$153.61M$119.38M$226.08M7 Day Performance-17.00%-4.32%-2.46%-2.03%1 Month Performance-23.51%-8.61%-4.07%0.07%1 Year Performance2.50%28.78%29.77%24.61% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics3.1555 of 5 stars$2.05-0.5%$11.71+471.4%+2.5%$109.75M$2.72M-1.93110Analyst ForecastPASGPassage Bio2.9528 of 5 stars$0.51+6.2%$9.00+1,652.0%-19.0%$29.77MN/A0.00130CHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.6385Analyst ForecastPYXSPyxis Oncology1.0178 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A-3.7160News CoverageGap UpHigh Trading VolumeKRROKorro Bio2.7373 of 5 stars$47.00+0.8%$142.17+202.5%+24.8%$436.84M$14.07M0.0070Analyst RevisionTSHATaysha Gene Therapies3.9247 of 5 stars$2.01-5.2%$6.63+229.6%+11.7%$434.48M$15.45M3.19180FHTXFoghorn Therapeutics2.6424 of 5 stars$7.86+0.8%$16.00+103.6%+91.2%$433.63M$34.15M0.00120TNGXTango Therapeutics2.4819 of 5 stars$4.08+6.0%$13.14+222.1%-46.4%$413.56M$36.53M-3.4690Gap DownVERVVerve Therapeutics2.4352 of 5 stars$4.55-6.0%$25.75+465.9%-63.2%$409.77M$11.76M0.00110LRMRLarimar Therapeutics3.678 of 5 stars$6.08-4.7%$20.43+236.0%+93.6%$407.09MN/A0.0030Analyst ForecastCGCCanopy Growth1.469 of 5 stars$3.76-1.8%$3.50-6.9%-36.3%$403.53M$220.27M0.001,029 Related Companies and Tools Related Companies PASG Alternatives CHMA Alternatives PYXS Alternatives KRRO Alternatives TSHA Alternatives FHTX Alternatives TNGX Alternatives VERV Alternatives LRMR Alternatives CGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RANI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
